Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker.

IGSF10 is a member of the immunoglobulin superfamily. Over the previous decade, growing proof has validated definitive correlations between individuals of the immunoglobulin superfamily and human diseases. However, the function of in pan-cancer stays unclear. We aimed to analyze the immunological and prognostic value of in pan-cancer. We utilized a vary of bioinformatic ways to inspect the function of in pan-cancer, including its correlation with prognosis, immune cell infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), DNA methyltransferases, genetic alteration, drug sensitivity, etc. We noticed low expression of in most cancer types. expression in tumor samples correlates with prognosis in most cancers. In most cancer types, expression was strongly related to immune cells infiltration, immune checkpoints, immune modulators, TMB, MSI, MMR, and DNA methyltransferases, among others. Functional enrichment analyses indicated that expression was involved in lymphocyte differentiation, cell molecules adhesion, etc. Furthermore, low expression could increase the drug sensitivity of many drugs. could serve as a novel prognostic marker and attainable immunotherapy target for several malignancies.